Home  /  Resource Library  /  Ibrutinib Plus Venetoclax for First Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Ibrutinib Plus Venetoclax for First Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Results of a phase II investigating ibrutinib combined with venetoclax for first line treatment of CLL.